A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Sponsor

Iovance Biotherapeutics, Inc. (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05361174

Collaborator

(none)

Enrollment

Locations

Arms

58.4

Anticipated Duration (Months)

26.5

Patients Per Site

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

Condition or Disease	Intervention/Treatment	Phase
Unresectable Melanoma Metastatic Melanoma Stage III Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer	Biological: IOV-4001	Phase 1/Phase 2

Detailed Description

This study is the first-in-human study of IOV-4001, a genetically modified autologous tumor- infiltrating lymphocytes (TIL) product. IOV-4001 is expected to have antitumor activity through its capacity to directly target and kill tumor cells in a manner that is similar to non-genome-edited TIL, but with the potential for enhanced antitumor activity due to disruption of PDCD1, the gene for programmed cell death protein-1 (PD-1).

Study Design

Study Type:

Interventional

Anticipated Enrollment :

53 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Actual Study Start Date :

Jul 20, 2022

Anticipated Primary Completion Date :

Jun 1, 2025

Anticipated Study Completion Date :

Jun 1, 2027

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort 1 Participants with unresectable or metastatic melanoma	Biological: IOV-4001 A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.
Experimental: Cohort 2 Participants with Stage III or IV non-small-cell lung cancer	Biological: IOV-4001 A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.

Arm

Intervention/Treatment

Experimental: Cohort 1

Participants with unresectable or metastatic melanoma

Biological: IOV-4001

A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.

Experimental: Cohort 2

Participants with Stage III or IV non-small-cell lung cancer

Biological: IOV-4001

Outcome Measures

Primary Outcome Measures

Phase I: Safety of IOV-4001 [Up to 1 Year or depending on when the recommended phase 2 dose is determined]
The safety of IOV-4001 will be assessed based on the totality of dose-limiting toxicity (DLT) and adverse event (AE) data collected during this phase
Phase 2: Objective Response Rate (ORR) [Up to 60 months]
To evaluate the proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by the investigator

Secondary Outcome Measures

CR Rate [Up to 60 months]
To evaluate the proportion of participants who have a confirmed CR per RECIST v1.1 as assessed by the investigator
Duration of Response (DOR) [Up to 60 months]
To evaluate the duration from the time that criteria are met for CR or PR per RECIST v1.1 as assessed by the investigator until disease progression or death due to any cause
Disease Control Rate (DCR) [Up to 60 months]
To evaluate the percentage of participants with a best overall confirmed response of CR or PR at any time plus stable disease (SD) per RECIST v1.1 as assessed by the investigator
Progression-free Survival (PFS) [Up to 60 months]
To evaluate the time from the date of IOV-4001 infusion until disease progression per RECIST v1.1 as assessed by the investigator or death due to any cause
Overall Survival (OS) [Up to 60 months]
To evaluate the time from the date of IOV-4001 infusion to death due to any cause.
Safety and Tolerability of IOV-4001 [Up to 60 months]
This will be characterized by the severity, seriousness, relationship to study treatment, and characteristics of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), study intervention-related adverse events (AEs), and AEs.
Feasibility of IOV-4001 [Up to 60 months]
This will be assessed by the proportion of participants who had tumor harvested and were treated without manufacturing delay or failure.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma (Cohort 1) or Stage III or IV NSCLC (Cohort 2).
Participants who have received the following previous therapy:
Cohort 1 (melanoma): Participants who have progressed within 12 weeks of last dose of anti-PD-1/PD-L1 blocking antibody and received BRAF/MEK inhibitor in those with BRAF mutations.
Cohort 2 (NSCLC): Participants who should have received no more than 3 prior lines of therapy and:

those without oncogene-driven tumors: Have progressed within 12 weeks after last dose of anti-PD-1/PD-L1 blocking antibody
those with oncogene-driven tumors: Have progressed during/after ≥1 targeted therapy AND either:
platinum doublet chemotherapy
Or within 12 weeks after last dose of anti-PD-1/PD-L1 blocking antibody

Participants who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Participants who is assessed as having at least one resectable lesion.
Participants who have at least one measurable lesion, following resection of the lesion for IOV-4001 generation.
Participants who have adequate organ function.
Cardiac function test required.
Pulmonary function test may be required.
Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months.

Exclusion Criteria:

Participants who have melanoma of uveal/ocular origin.
Participants who have symptomatic untreated brain metastases.
Participants who have had a history of allogeneic organ transplant or any form of cell therapy involving prior conditioning chemotherapy within the past 20 years.
Participants who require systemic steroid therapy > 10 mg/day prednisone or another steroid equivalent dose.
Participants who have any form of primary immunodeficiency.
Participants who have another primary malignancy within the previous 3 years.
Participants who have received or will receive a live or attenuated vaccination within 28 days prior to the start of the NMA-LD.